Antibodies to interleukin-9 and uses thereof
Through antibodies that specifically bind IL-9 to interfere with the IL-9 signaling pathway, the side effects of existing drugs and the limitation of long-term use are solved, and effective treatment of respiratory diseases, autoimmune diseases and hematologic cancers is achieved, significantly improving symptoms and disease progression.
Patent Information
- Application Number
- CN202411115474.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-06-20
- Filing Date
- 2023-06-13
- Publication Date
- 2024-11-08
AI Technical Summary
Existing drugs for the treatment of respiratory diseases, autoimmune diseases and hematologic cancers such as NSAID, corticosteroids and immunosuppressants have side effects and limitations on long-term use, which cannot effectively change disease progression, and lack new therapies for long-term use.
Develop antibodies and antigen-binding fragments specifically binding to interleukin-9 (IL-9) for the prevention or treatment of diseases associated with abnormal expression of IL-9, including respiratory diseases, autoimmune diseases and hematologic cancers, through specific Sexual binding interferes with IL-9's signaling pathways, blocking its proinflammatory and protumour effects.
Effectively reduce symptoms, reduce inflammatory and fibrosis scores, significantly improve lung tissue structure, provide potential long-term treatment options, reduce damage to the immune system, and increase patients' resistance to infection.
Smart Images

Figure BDA0004993495520000251 
Figure BDA0004993495520000271 
Figure BDA0004993495520000281
Abstract
Description
[0001] This application is a divisional application of a Chinese patent application with an application date of June 13, 2023, application number 202310703169.2, and invention name “Antibodies against interleukin-9 and their uses”. Field of the Invention
[0002] The present disclosure relates to antibodies that specifically bind IL-9, and uses of these antibodies, particularly their use in respiratory diseases, autoimmune diseases, and hematological cancers. Technical Background
[0003] Interleukin-9 (IL-9) is a 28-30 kDa monomeric glycosylated polypeptide expressed by activated T cells and mast cells, and plays a key role in many antigen-induced responses. IL-9 acts through the interleukin-9 receptor (IL-9R), which can stimulate cell proliferation and prevent cell apoptosis. After IL-9R is activated, it activates different pathways through different signal transductions, such as the Janus kinase (JAK) signaling pathway and STAT proteins (including STAT1, STAT3, and STAT5), thereby linking IL-9 to various biological processes. IL-9 can affect many effector cells, such as effector T cells, B cells, innate lymphocytes, mast cells, polymorphonuclear cells, epithelial cells, and smooth muscle cells, and plays an important role in inflammatory immune regulation.
[0004] IL-9 plays a key role in promoting cellular and humoral immune responses, making it a potential target for therapeutic intervention. According to previous reports, IL-9 plays an important role in the occurrence and development of respiratory diseases, autoimmune diseases, and hematological cancers, and its mechanism may be related to the function of IL-9 and its secreting cells Th9.
[0005] Respiratory diseases can be caused by infection with pathogens such as various viruses or bacteria, as well as allergic reactions, while autoimmune diseases are caused by the body's immune response to its own antibodies, which leads to damage to its own tissues. The former is mainly manifested as inflammation of respiratory tissues such as the lungs, while the latter can cause non-infectious inflammatory changes in multiple organ tissues such as joints, synovium, soft tissues, and connective tissues throughout the body. These two types of diseases have many similarities in many aspects such as pathogens, pathogenesis, and pathological changes, and also have similarities in treatment approaches and drug targets.
[0006] The treatment of autoimmune diseases is also very difficult and requires long-term treatment. Therapies currently used for inflammatory diseases include symptomatic drug treatment and immunosuppressants. Among them, drugs with analgesic and anti-inflammatory effects in the treatment of improving symptoms include non-steroidal anti-inflammatory drugs (NSAIDs). However, NSAIDs cannot change the progression of the disease, and they often cause gastrointestinal side effects, affect the lower digestive tract, cause perforation or aggravate inflammatory bowel disease and produce nephrotoxicity. Corticosteroids are another type of drug commonly used to control inflammatory symptoms. Corticosteroids, like NSAIDs, do not change the natural progression of the disease. Therefore, when the drug is discontinued, the clinical manifestations of active diseases usually reappear. And long-term treatment with corticosteroids will cause serious adverse reactions in patients, which greatly limits its long-term use. Immunosuppressants are also a commonly used treatment option. Similarly, long-term use of immunosuppressants can damage the patient's immune system, thereby making the patient defenseless against infection. Therefore, it is necessary to find new therapies that can be used for autoimmune diseases for a long time.
[0007] In addition, in hematological cancers such as Hodgkin lymphoma, IL-9 is thought to act in a paracrine manner, promoting tumor progression by stimulating and activating TH2-type lymphocytes infiltrating the lymphoma and interacting with other cells that make up the tumor, such as mast cells, monocytes, and eosinophils. SUMMARY OF THE INVENTION
[0009] The present disclosure provides antibodies that specifically bind to IL-9, as well as nucleic acids encoding the antibodies, vectors comprising the nucleic acids, and host cells comprising the nucleic acids or the vectors. Pharmaceutical compositions comprising the antibodies, and uses of the antibodies and pharmaceutical compositions are also disclosed, particularly uses of the antibodies for preventing or treating respiratory diseases, autoimmune diseases, and hematologic cancers.
[0010] Accordingly, in one aspect, the present disclosure provides an antibody or antigen-binding fragment thereof that specifically binds to interleukin-9 (IL-9), comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein
[0011] (i) VH comprises CDR-H1, CDR-H2 and CDR-H3 having the amino acid sequences shown in SEQ ID NOs: 1-3, respectively, and VL comprises CDR-L1, CDR-L2 and CDR-L3 having the amino acid sequences shown in SEQ ID NO: 5, amino acid SAS and SEQ ID NO: 6, respectively; or
[0012] (ii) VH comprises CDR-H1, CDR-H2 and CDR-H3 having the amino acid sequences shown in SEQ ID NOs: 8-10, respectively, and VL comprises CDR-L1, CDR-L2 and CDR-L3 having the amino acid sequences shown in SEQ ID NO: 12, amino acid AAT and SEQ ID NO: 13, respectively; or
[0013] (iii) VH comprises CDR-H1, CDR-H2 and CDR-H3 having the amino acid sequences shown in SEQ ID NOs: 15-17, respectively, and VL comprises CDR-L1, CDR-L2 and CDR-L3 having the amino acid sequences shown in SEQ ID NO: 19, amino acid YAS and SEQ ID NO: 20, respectively; or
[0014] (iv) VH comprises CDR-H1, CDR-H2 and CDR-H3 having the amino acid sequences shown as SEQ ID NOs: 22-24, respectively, and VL comprises CDR-L1, CDR-L2 and CDR-L3 having the amino acid sequences shown as SEQ ID NO: 12, amino acid AAT and SEQ ID NO: 13, respectively.
[0015] In some embodiments of the antibodies or antigen-binding fragments thereof of the present disclosure,
[0016] (i) the VH comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO:4, and the VL comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO:7; or
[0017] (ii) the VH comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 11, and the VL comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 14; or
[0018] (iii) the VH comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 18, and the VL comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 21; or
[0019] (iv) the VH comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99% or 100% sequence identity to SEQ ID NO:25, and the VL comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99% or 100% sequence identity to SEQ ID NO:14.
[0020] In some embodiments,
[0021] (i) VH comprises the amino acid sequence shown in SEQ ID NO:4, and VL comprises the amino acid sequence shown in SEQ ID NO:7; or
[0022] (ii) VH comprises the amino acid sequence shown in SEQ ID NO: 11, and VL comprises the amino acid sequence shown in SEQ ID NO: 14; or
[0023] (iii) VH comprises the amino acid sequence shown in SEQ ID NO: 18, and VL comprises the amino acid sequence shown in SEQ ID NO: 21; or
[0024] (iv) VH comprises the amino acid sequence shown in SEQ ID NO:25, and VL comprises the amino acid sequence shown in SEQ ID NO:14.
[0025] In some embodiments of the antibodies or antigen-binding fragments thereof of the present disclosure, VH comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence selected from any one of SEQ ID NOs: 26-29, and VL comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence selected from any one of SEQ ID NOs: 30-33.
[0026] In some embodiments, VH comprises the amino acid sequence shown in any one of SEQ ID NOs: 26-29, and VL comprises the amino acid sequence shown in any one of SEQ ID NOs: 30-33.
[0027] In a preferred embodiment,
[0028] (i) VH comprises the amino acid sequence shown in SEQ ID NO:26, and VL comprises the amino acid sequence shown in SEQ ID NO:31; or
[0029] (ii) VH comprises the amino acid sequence shown in SEQ ID NO:26, and VL comprises the amino acid sequence shown in SEQ ID NO:33; or
[0030] (iii) VH comprises the amino acid sequence shown in SEQ ID NO:27, and VL comprises the amino acid sequence shown in SEQ ID NO:33; or
[0031] (iv) VH comprises the amino acid sequence shown in SEQ ID NO:28, and the VL comprises the amino acid sequence shown in SEQ ID NO:33.
[0032] In some embodiments of the antibodies or antigen-binding fragments thereof of the present disclosure, the antibody can be selected from IgG, IgA, IgM, IgE, and IgD isotypes, such as IgG1, IgG2, IgG3, and IgG4 subtypes.
[0033] In some embodiments, the antibody can be selected from a murine antibody, a chimeric antibody, a humanized antibody, and a fully human antibody.
[0034] In some embodiments, the antigen binding fragment may be selected from Fab, Fab', F(ab')2, Fv, scFv and ds-scFv.
[0035] In some embodiments, the antibody can be a bispecific antibody or a multispecific antibody.
[0036] In another aspect, the present disclosure provides a nucleic acid comprising a nucleotide sequence encoding an antibody or antigen-binding fragment thereof of the present disclosure.
[0037] In yet another aspect, the present disclosure provides a vector comprising a nucleotide sequence encoding the antibody or antigen-binding fragment thereof of the present disclosure.
[0038] In yet another aspect, the present disclosure provides a host cell comprising the nucleic acid of the present disclosure or the vector of the present disclosure.
[0039] In yet another aspect, the present disclosure provides a pharmaceutical composition comprising the antibody or antigen-binding fragment thereof of the present disclosure, and a pharmaceutically acceptable carrier or excipient.
[0040] In some embodiments of the pharmaceutical composition of the present disclosure, the pharmaceutical composition further comprises a second therapeutic agent. In some embodiments, the second therapeutic agent may be selected from antibodies, chemotherapeutic agents and small molecule drugs. In some embodiments, the second therapeutic agent may be selected from antiviral agents, antibacterial agents, antifungal agents, antiangiogenic agents, TNF-α antagonists, immunomodulators, anticancer agents, mast cell regulators, anti-inflammatory agents, antihistamines, and common Chinese medicine active ingredients and extracts, and combinations thereof.
[0041] In another aspect, the present disclosure provides a method for preventing or treating a disease associated with abnormal expression of IL-9 in a subject, comprising administering to the subject a therapeutically effective amount of the antibody or antigen-binding fragment thereof of the present disclosure or the pharmaceutical composition of the present disclosure.
[0042] In yet another aspect, the present disclosure provides the antibody or antigen-binding fragment thereof of the present disclosure or the pharmaceutical composition of the present disclosure for use in preventing or treating a disease associated with abnormal expression of IL-9 in a subject.
[0043] In yet another aspect, the present disclosure provides use of the antibody or antigen-binding fragment thereof or the pharmaceutical composition of the present disclosure in the preparation of a medicament for preventing or treating a disease associated with abnormal expression of IL-9 in a subject.
[0044] In some embodiments of the above aspects of the present disclosure, the disease associated with abnormal expression of IL-9 may be a respiratory disease. In some embodiments, the respiratory disease may be selected from acute infectious pneumonia, hypersensitivity pneumonitis, bronchial asthma, chronic obstructive pulmonary disease and pulmonary tissue fibrosis.
[0045] In some embodiments, the disease associated with abnormal expression of IL-9 can be an autoimmune disease. In some embodiments, the autoimmune disease can be selected from systemic lupus erythematosus, rheumatoid arthritis, systemic vasculitis, scleroderma, dermatomyositis, mixed connective tissue disease, allergic rhinitis, allergic conjunctivitis, autoimmune hemolytic anemia, thyroid autoimmune disease, ulcerative colitis, Sjögren's syndrome, psoriatic arthritis, multiple sclerosis, chronic lymphocytic thyroiditis, insulin-dependent diabetes mellitus, myasthenia gravis, pernicious anemia with chronic atrophic gastritis, Goodpasture's syndrome, pemphigus vulgaris, pemphigoid, multiple sclerosis, acute idiopathic polyneuritis and autoimmune adrenal insufficiency.
[0046] In some embodiments, the disease associated with abnormal expression of IL-9 can be a blood cancer, such as leukemia, plasma cell malignancy or lymphoma. In some embodiments, the blood cancer can be selected from chronic myeloid leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, acute lymphocytic leukemia, multiple myeloma, monoclonal gammopathy of undetermined significance (MGUS), non-Hodgkin's lymphoma and Hodgkin's lymphoma.
[0047] In some embodiments of the above aspects of the disclosure, the method further comprises administering a second therapeutic agent to the subject. In some embodiments, the antibody or antigen-binding fragment thereof of the disclosure, or the pharmaceutical composition of the disclosure is administered in combination with a second therapeutic agent.
[0048] In some embodiments, the second therapeutic agent can be selected from antibodies, chemotherapeutic agents and small molecule drugs. In some embodiments, the second therapeutic agent can be selected from antiviral agents, antibacterial agents, antifungal agents, antiangiogenic agents, TNF-α antagonists, immunomodulators, anticancer agents, mast cell regulators, anti-inflammatory agents, antihistamines, and common traditional Chinese medicine active ingredients and extracts, and combinations thereof. BRIEF DESCRIPTION OF THE DRAWINGS
[0049] An understanding of the features and advantages of the present invention may be obtained by referring to the following detailed description and accompanying drawings which describe exemplary embodiments utilizing the principles of the invention, in which:
[0050] Figure 1 The SDS-PAGE test results of Fc-IL-9 and IL-9-His recombinant proteins are shown, wherein lane M is a protein marker, lane 9 is Fc-IL-9 recombinant protein, and lane 1 is IL-9-His recombinant protein.
[0051] Figure 2 The FACS results of preparing CHO-S-IL-9 membrane-expressing cell lines are shown. NC (negative control) is PBS, and the control cells are CHO-S.
[0052] Figure 3 The blocking activity flow cytometry results of the purified antibodies are shown. The positive control is the IL-9 positive antibody 7F3com (see patent CN1809383A).
[0053] Figure 4 Schematic diagram of the structures of pcDNA3.4-IgG1 and pcDNA3.4-IgKc expression vectors is shown.
[0054] Figure 5 The blocking activity flow cytometry results and EC of the chimeric antibody are shown. 50 The positive control was 7F3com.
[0055] Figure 6A-6B The ELISA test results of humanized antibodies are shown ( Fig. 6A ) and blocking activity flow cytometry results ( Figure 6B ). In ELISA, the controls were 38-D8-C7-G9 chimeric antibody (CA1) and 7F3com; in flow cytometry, the control was 38-D8-C7-G9 chimeric antibody (CA1).
[0056] Figures 7A-7C The results of detecting the affinity of the humanized antibody by ForteBio (BLI) are shown. Fig. 7A It is a 38-D8-C7-G9 chimeric antibody (CA1), Figure 7B It is a humanized VH1-VL2 antibody. Figure 7C It is a humanized VH1-VL4 antibody.
[0057] Figures 8A-8B Shown are the changes in body weight over time in the bleomycin mouse model group and the silica mouse model group.
[0058] Figures 9A-9B The HE staining and inflammatory score results of the bleomycin mouse model group are shown (**=P<0.01; ***=P<0.001).
[0059] Figures 10A-10B The results of Masson staining and fibrosis score of the bleomycin mouse model group are shown (ns: not significant; *=P<0.05; ***=P<0.001).
[0060] Figures 11A-11B HE staining and inflammatory score results of the silica mouse model group are shown (*=P<0.05; **=P<0.01; ***=P<0.001).
[0061] Figures 12A-12B Masson staining and fibrosis score results of the silica mouse model group are shown (*=P<0.05; ***=P<0.001). DETAILED DESCRIPTION OF THE INVENTION
[0063] The present disclosure provides antibodies or antigen-binding fragments thereof with high affinity for IL-9, which can be used to treat respiratory diseases associated with IL-9 expression and / or activity (such as acute infectious pneumonia, allergic pneumonia, bronchial asthma, chronic obstructive pulmonary disease, and pulmonary tissue fibrosis caused by various reasons, idiopathic pulmonary fibrosis, etc.), autoimmune diseases (such as systemic lupus erythematosus, rheumatoid arthritis, systemic vasculitis, scleroderma, dermatomyositis, mixed connective tissue disease, autoimmune hemolytic anemia, thyroid autoimmune disease, ulcerative colitis, Sjögren's syndrome, psoriatic arthritis, multiple sclerosis, chronic hemorrhage, etc.), The main medical conditions that may be considered to be considered are: acute lymphocytic thyroiditis, insulin-dependent diabetes mellitus, myasthenia gravis, pernicious anemia with chronic atrophic gastritis, Goodpasture's syndrome, pemphigus vulgaris, pemphigoid, multiple sclerosis, acute idiopathic polyneuritis, autoimmune adrenal insufficiency, and hematologic cancers such as leukemia (e.g., chronic myeloid leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, acute lymphocytic leukemia), plasma cell malignancies (e.g., multiple myeloma, monoclonal gammopathy of undetermined significance (MGUS)), or lymphomas (e.g., non-Hodgkin's lymphoma and Hodgkin's lymphoma)
[0064] Any aspect or embodiment described herein may be combined with any other aspect or embodiment disclosed herein. Although the disclosure has been described in conjunction with the detailed description of the disclosure, the foregoing description is intended to illustrate rather than limit the scope of the disclosure, and the scope of the disclosure is limited by the scope of the appended claims. Other aspects, advantages and modifications are within the scope of the following claims. The patents and scientific literature mentioned herein establish the knowledge available to those skilled in the art. All Chinese patents and published or unpublished Chinese patent applications cited herein are incorporated herein by reference. All disclosed foreign patents and patent applications cited herein are incorporated herein by reference. All other disclosed references, dictionaries, documents, manuscripts and scientific literature cited herein are incorporated herein by reference. From the following detailed description including embodiments and claims, other features and advantages of the disclosure will be apparent.
[0065] In order to more easily understand the present disclosure, certain terms are first defined below. Additional definitions of the following terms and other terms are set forth throughout the specification.
[0066] Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art.
[0067] It should be noted that as used herein and in the appended claims, the singular forms "a," "an," and "the" include plural references unless the context clearly dictates otherwise. Thus, the terms "a," "an," "one or more," and "at least one" may be used interchangeably. Similarly, the terms "comprising," "including," "containing," and "having" may be used interchangeably.
[0068] When the terms "comprises", "includes", "contains" and "have" are used herein and in the appended claims, they do not exclude other elements. For the purpose of the present invention, the term "consisting of" is considered a preferred embodiment of the term "comprising".
[0069] The present disclosure provides an antibody or an antigen-binding fragment thereof that specifically binds to interleukin-9 (IL-9), comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein
[0070] (i) VH comprises CDR-H1, CDR-H2 and CDR-H3 having the amino acid sequences shown in SEQ ID NOs: 1-3, respectively, and VL comprises CDR-L1, CDR-L2 and CDR-L3 having the amino acid sequences shown in SEQ ID NO: 5, amino acid SAS and SEQ ID NO: 6, respectively; or
[0071] (ii) VH comprises CDR-H1, CDR-H2 and CDR-H3 having the amino acid sequences shown in SEQ ID NOs: 8-10, respectively, and VL comprises CDR-L1, CDR-L2 and CDR-L3 having the amino acid sequences shown in SEQ ID NO: 12, amino acid AAT and SEQ ID NO: 13, respectively; or
[0072] (iii) VH comprises CDR-H1, CDR-H2 and CDR-H3 having the amino acid sequences shown in SEQ ID NOs: 15-17, respectively, and VL comprises CDR-L1, CDR-L2 and CDR-L3 having the amino acid sequences shown in SEQ ID NO: 19, amino acid YAS and SEQ ID NO: 20, respectively; or
[0073] (iv) VH comprises CDR-H1, CDR-H2 and CDR-H3 having the amino acid sequences shown as SEQ ID NOs: 22-24, respectively, and VL comprises CDR-L1, CDR-L2 and CDR-L3 having the amino acid sequences shown as SEQ ID NO: 12, amino acid AAT and SEQ ID NO: 13, respectively.
[0074] As used in this disclosure, the term "antibody" refers to an immunoglobulin molecule that has the ability to specifically bind to a specific antigen. Antibodies typically contain a variable region and a constant region in each heavy chain and light chain. The variable regions of the antibody heavy and light chains contain a binding domain that interacts with the antigen. The constant region of the antibody can mediate the binding of the immunoglobulin to host tissues or factors, including various cells of the immune system (such as effector cells) and components of the complement system. Therefore, most antibodies have a heavy chain variable region (VH) and a light chain variable region (VL), which together form the antibody portion that binds to the antigen.
[0075] The "heavy chain variable region" (VH) or "light chain variable region" (VL) consists of a "framework" (FR) region interspersed with three "complementarity determining regions" or "CDRs". The framework region is used to adjust the CDRs for specific binding to antigenic epitopes. The CDRs contain the amino acid residues in the antibody that are primarily responsible for antigen binding. From the amino terminus to the carboxyl terminus, both the VH and VL domains contain the following FR and CDR regions: FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4. CDRs 1, 2, and 3 of the VH domain are also referred to herein as CDR-H1, CDR-H2, and CDR-H3, respectively; CDRs 1, 2, and 3 of the VL domain are also referred to herein as CDR-L1, CDR-L2, and CDR-L3, respectively.
[0076] The amino acid assignments for each VH and VL domain follow any conventional definition of CDRs. Conventional definitions include the Kabat definition (Kabat, Sequences of Proteins of Immunological Interest (National Institutes of Health, Bethesda, MD, 1987 and 1991)); the Chothia definition (Chothia & Lesk, J. Mol. Biol. 196: 901-917, 1987; Chothia et al., Nature 342: 878-883, 1989); a composite of Chothia and Kabat CDRs; the AbM definition used by Oxford Molecular's antibody modeling software; and the CONTACT definition of Martin et al. (www.bioinfo.org.uk / abs). Kabat provides a widely used numbering convention (Kabat numbering system) in which corresponding residues between different heavy chains or between different light chains are assigned the same number. The present disclosure may use CDRs defined according to any of these numbering systems. In some embodiments, the Kabat-defined CDRs are used. In some embodiments, the CDRs defined by Chothia are used. In some embodiments, the CDRs defined by Chothia are used. In some embodiments, the CDRs defined by Chothia and Kabat are used in combination. In some embodiments, the CDRs defined by AbM are used. In some embodiments, the CDRs defined by CONTACT are used.
[0077] As used in this disclosure, the term "binding" or "specific binding" refers to a non-random binding reaction between two molecules, such as a non-random binding reaction between an antibody and its target antigen. The binding specificity of an antibody can be determined based on affinity and / or avidity. Affinity is usually represented by the equilibrium constant (KD) for the dissociation of the antigen and the antibody, and is a measure of the strength of binding between an antigenic determinant and an antigen binding site of an antibody: the smaller the KD value, the stronger the binding strength between the antigenic determinant and the antibody. Alternatively, affinity can also be expressed as an affinity constant (KA), which is 1 / KD. KD can be derived from K off / K on KA can be calculated from the quotient of K on / K off The quotient of K is calculated. on For example, K refers to the binding rate constant of an antibody to an antigen, while off Refers to, for example, the dissociation rate constant of an antibody from an antigen. on and K off The method can be performed by techniques known to those skilled in the art (such as or KinExA) assay.
[0078] Typically, antibodies will be present at 10 -5 Up to 10 -12 The binding is carried out with a dissociation constant (KD) of 10 M or less, preferably with a KD of 10 -7 Up to 10 -12 M or less, more preferably 10 -8 Up to 10 -12 M, and / or bind with a dissociation constant (KD) of at least 10 7 M -1 , preferably at least 10 8 M -1 , more preferably at least 10 9 M -1 , for example at least 10 12 M -1 It is generally considered that any binding affinity greater than 10 -4 The KD value of M represents non-specific binding. Specific binding of an antibody to an antigen or antigenic determinant can be determined by any suitable means known per se, including, for example, Scatchard analysis and / or competitive binding assays, such as radioimmunoassay (RIA), enzyme immunoassay (EIA) and sandwich competition assays and different variations known per se in the art.
[0079] In some embodiments of the antibodies or antigen-binding fragments thereof of the present disclosure,
[0080] (i) the VH comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO:4, and the VL comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO:7; or
[0081] (ii) the VH comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 11, and the VL comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 14; or
[0082] (iii) the VH comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 18, and the VL comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 21; or
[0083] (iv) the VH comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99% or 100% sequence identity to SEQ ID NO:25, and the VL comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99% or 100% sequence identity to SEQ ID NO:14.
[0084] In some embodiments of the antibodies or antigen-binding fragments thereof of the present disclosure, VH comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence selected from any one of SEQ ID NOs: 26-29, and VL comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence selected from any one of SEQ ID NOs: 30-33.
[0085] In a preferred embodiment,
[0086] (i) VH comprises the amino acid sequence shown in SEQ ID NO:26, and VL comprises the amino acid sequence shown in SEQ ID NO:31;
[0087] (ii) VH comprises the amino acid sequence shown in SEQ ID NO:26, and VL comprises the amino acid sequence shown in SEQ ID NO:33; or
[0088] (iii) VH comprises the amino acid sequence shown in SEQ ID NO:27, and VL comprises the amino acid sequence shown in SEQ ID NO:33; or
[0089] (iv) VH comprises the amino acid sequence shown in SEQ ID NO:28, and VL comprises the amino acid sequence shown in SEQ ID NO:33.
[0090] As used herein, "sequence identity" refers to the degree of identity between any given query sequence and subject sequence. Those skilled in the art will readily understand how to determine the identity of two polypeptides (e.g., an unmodified peptide and a peptide variant). For example, the identity can be calculated after aligning the two sequences to maximize their identity, for example, by introducing gaps. Another method for calculating identity can be implemented by a disclosed algorithm. Non-limiting examples of such mathematical algorithms include the algorithm of Myers and Miller (1988) CABIOS 4:11-17, the local homology algorithm of Smith et al. (1981) Adv. Appl. Math. 2:482, the homology alignment algorithm of Needleman and Wunsch (1970) J. Mol. Biol. 48:443-453, the method for searching homology of Pearson and Lipman (1988) Proc. Natl. Acad. Sci. 85:2444-2448, and a modification of the algorithm of Karlin and Altschul (1990) Proc. Natl. Acad. Sci. USA 87:2264, the algorithm described in Karlin and Altschul (1993) Proc. Natl. Acad. Sci. USA 90:5873-5877. By using a program based on such a mathematical algorithm, a sequence comparison (i.e., comparison) for determining sequence identity can be implemented. The program can be suitably executed by a computer. Examples of such programs include, but are not limited to, CLUSTAL, ALIGN programs (2.0 versions) of the PC / Gene program and GAP, BESTFIT, BLAST, FASTA, and TFASTA of the Wisconsin genetics software package. The comparison using these programs can be implemented, for example, by using initial parameters.
[0091] In addition, when determining the degree of sequence identity between two amino acid sequences, a skilled person may consider so-called "conservative" amino acid substitutions, which can generally be described as amino acid substitutions in which an amino acid residue is replaced with another amino acid residue of similar chemical structure, which has little or substantially no effect on the function, activity or other biological properties of the polypeptide. Such conservative amino acid substitutions are well known in the art.
[0092] Such conservative substitutions are preferably substitutions in which one amino acid from the following groups (a) to (e) is replaced by another amino acid residue from the same group: (a) small aliphatic, non-polar or weakly polar residues: Ala, Ser, Thr, Pro and Gly; (b) polar, negatively charged residues and their (uncharged) amides: Asp, Asn, Glu and Gln; (c) polar, positively charged residues: His, Arg and Lys; (d) large aliphatic, non-polar residues: Met, Leu, He, Val and Cys; and (e) aromatic residues: Phe, Tyr and Trp.
[0093] Particularly preferred conservative substitutions are as follows: Ala to Gly or to Ser; Arg to Lys; Asn to Gln or to His; Asp to Glu; Cys to Ser; Gln to Asn; Glu to Asp; Gly to Ala or to Pro; His to Asn or to Gln; Ile to Leu or to Val; Leu to Ile or to Val; Lys to Arg, to Gln or to Glu; Met to Leu, to Tyr or to Ile; Phe to Met, to Leu or to Tyr; Ser to Thr; Thr to Ser; Trp to Tyr; Tyr to Trp; and / or Phe to Val, to Ile or to Leu.
[0094] In some embodiments, the antibodies and antigen-binding fragments thereof disclosed herein include variants, which may include one or more amino acid modifications. Substitutions, deletions, insertions, additions, or any combination thereof may be included in a single variant, as long as the variant can specifically bind to the antigen. Methods and techniques for preparing variants are well known to those skilled in the art.
[0095] In some embodiments, the antibody can be selected from IgG, IgA, IgM, IgE and IgD isotypes, such as IgG1, IgG2, IgG3 and IgG4 subtypes. In some embodiments, the antibody can be selected from mouse antibodies, chimeric antibodies, humanized antibodies and fully human antibodies. In some embodiments, the antigen binding fragment can be selected from Fab, Fab', F(ab')2, Fv, scFv and ds-scFv. In some embodiments, the antibody can be a bispecific antibody or a multispecific antibody.
[0096] The term "antibody" used in the present disclosure should be understood in its broadest sense and includes monoclonal antibodies (including full-length monoclonal antibodies), polyclonal antibodies, antibody fragments, and multispecific antibodies (e.g., bispecific antibodies) comprising at least two antigen-binding regions. The antibody may contain additional modifications, such as non-naturally occurring amino acids, mutations in the Fc region, and mutations in glycosylation sites. Antibodies also include post-translationally modified antibodies, fusion proteins containing antigenic determinants of antibodies, and immunoglobulin molecules containing any other modifications to the antigen recognition site, as long as these antibodies exhibit the desired biological activity.
[0097] In some embodiments, antibodies include chimeric antibodies, such as humanized forms of murine antibodies. Such humanized antibodies can be prepared by known techniques, and provide advantages of reducing immunogenicity when the antibodies are applied to people. In one embodiment, humanized antibodies include the variable region (or only its antigen binding site) of murine antibodies and the constant region derived from human antibodies. Alternatively, humanized antibody fragments may include the antigen binding site of murine antibodies and the variable region fragments (lacking antigen binding sites) derived from human antibodies. The procedures for producing chimeric antibodies and further engineered antibodies include those described in the following: Riechmann et al., (Nature 332:323, 1988); Liu et al., (PNAS 84:3439, 1987); Larrick et al., (Bio / Technology 7:934, 1989); and Winter and Harris (TIPS 14:139, May, 1993). Procedures for transgenic production of antibodies can be found in GB 2,272,440, US Pat. Nos. 5,569,825 and 5,545,806.
[0098] Antibodies produced by genetic engineering methods (such as chimeric and humanized antibodies) can be used, which contain both human and non-human parts and can be made using standard recombinant DNA techniques. Such chimeric and humanized antibodies can be produced by genetic engineering using standard DNA techniques known in the art.
[0099] As used in this disclosure, the term "antigen-binding fragment" of an antibody refers to one or more antibody fragments that retain the ability to specifically bind to an antigen (eg, IL-9). It has been shown that the antigen-binding function of an antibody can be performed by fragments of a full-length antibody. Examples of antigen-binding fragments include (i) Fab fragments, which are monovalent fragments consisting of VH, VL, CH1 and CL domains; (ii) F(ab')2 fragments, which are bivalent fragments comprising two Fab fragments linked by a disulfide bond in the hinge region; (iii) Fab' fragments, which are essentially Fab but have a partial hinge region (see, FUNDAMENTAL IMMUNOLOGY (Paul ed., 3.sup.rd ed. 1993)); (iv) Fd fragments, which consist of VH and CH1 domains; (v) Fd' fragments, which have VH and CH1 domains and one or more cysteine residues at the C-terminus of the CH1 domain; (vi) Fv fragments, which consist of the VH and VL domains of a single arm of an antibody; (vii) dAb fragments (Ward et al. (1989) Nature 341: 544-546), which consists of a VH domain; (viii) a single complementarity determining region (CDR); and (ix) a nanobody, which is a heavy chain variable region comprising a single variable domain and two constant domains. In addition, although the two domains of the Fv fragment, VH and VL, are encoded by independent genes, they can be connected by a synthetic linker using recombinant methods, which enables them to form a single protein chain in which the VH and VL regions are paired to form a monovalent molecule (called a single-chain Fv (scFv); see, for example, Bird et al. (1988) Science 242, 423-426; and Huston et al. (1988) Proc. Natl. Acad. Sci. USA 85, 5879-5883). Such single-chain antibodies are also intended to be included in the term "antigen-binding fragment" of an antibody. Additionally, the term also includes "linear antibodies" containing a pair of tandem Fd fragments (VH-CH1-VH-CH1) that together with complementary light chain polypeptides form an antigen binding region, as well as modified versions of any of the foregoing fragments that retain antigen binding activity.
[0100] These antigen-binding fragments can be obtained using conventional techniques known to those with skill in the art, and the fragments screened for utility in the same manner as are intact antibodies.
[0101] In one aspect, the present disclosure provides a nucleic acid comprising a nucleotide sequence encoding an antibody or antigen-binding fragment thereof of the present disclosure.
[0102] The terms "nucleic acid", "nucleotide", "nucleotide sequence" are used interchangeably and refer to oligomers and polymers of any length that are essentially composed of nucleotides (such as deoxyribonucleotides and / or ribonucleotides). Nucleic acids can contain purine and / or pyrimidine bases and / or other natural (e.g., xanthine, inosine, hypoxanthine), chemically or biochemically modified (e.g., methylated), non-natural or derived nucleotide bases. The backbone of the nucleic acid can contain sugars and phosphate groups that are typically present in RNA or DNA, and / or one or more modified or substituted sugars and / or one or more modified or substituted phosphate groups. Modifications of phosphate groups or sugars can be introduced to improve stability, resistance to enzymatic degradation, or some other useful properties. "Nucleic acid" can be, for example, double-stranded, partially double-stranded or single-stranded. When single-stranded, the nucleic acid can be the sense strand or the antisense strand. "Nucleic acid" can be circular or linear. As used herein, the term "nucleic acid" encompasses DNA and RNA, including genomes, pre-mRNA, mRNA, cDNA, recombinant or synthetic nucleic acids containing vectors. For the purposes of the uses described herein, it will be understood that the polynucleotides may be modified by any method available in the art.
[0103] Those skilled in the art will appreciate that, due to the degeneracy of the genetic code, many different polynucleotides and nucleic acids can encode the same polypeptide. In addition, it should be understood that the skilled person can use conventional techniques to make nucleotide substitutions that do not affect the polypeptide sequence encoded by the polynucleotides described herein to reflect the codon usage of any specific host organism in which the polypeptide is to be expressed.
[0104] In yet another aspect, the present disclosure provides a vector comprising a nucleic acid of the present disclosure.
[0105] As used herein, "vector" refers to a nucleic acid delivery vehicle into which nucleotides can be inserted. When a vector can express the protein encoded by the inserted nucleotides, the vector is called an expression vector. The vector can be introduced into a host cell by transformation, transduction or transfection, and the genetic material elements it carries are then expressed in the host cell. Vectors are recognized by those skilled in the art and include, but are not limited to: (1) plasmids; (2) phagemids; (3) cosmids; (4) artificial chromosomes, such as yeast artificial chromosomes, bacterial artificial chromosomes or P1-derived artificial chromosomes; (5) bacteriophages, such as lambda phage or M13 phage; and (6) animal viruses, such as retroviruses, adenoviruses, adeno-associated viruses, lentiviruses, herpes viruses, poxviruses, and baculoviruses. A vector may contain a variety of elements for controlling expression, including but not limited to promoter sequences, transcription initiation sequences, enhancer sequences, selection elements and reporter genes; in addition, the vector may also contain a replication initiation site.
[0106] The recombinant expression vector can be any suitable recombinant expression vector. Suitable vectors include vectors designed for reproduction and amplification or for expression or both, such as plasmids and viruses. For example, vectors can be selected from pUC series (Fermentas Life Sciences, Glen Burnie, Md.), pBluescript series (Stratagene, LaJolla, CA), pET series (Novagen, Madison, Wis.), pGEX series (Pharmacia Biotech, Uppsala, Sweden) and pEX series (Clontech, Palo Alto, Calif.). Phage vectors, such as λGT10, λGT11, λZapII (Stratagene), λEMBL4 and λNM1149, can also be used. Examples of plant expression vectors that can be used for the present disclosure include pBI01, pBI101.2, pBI101.3, pBI121 and pBIN19 (Clontech). Examples of animal expression vectors that can be used in the present disclosure include pcDNA, pEUK-Cl, pMAM, and pMAMneo (Clontech).
[0107] In another aspect, the present disclosure provides a host cell comprising a nucleic acid of the present disclosure or a vector of the present disclosure.
[0108] As used herein, the term "host cell" refers to a cell into which an expression vector has been introduced. Any cell can be used as a host cell for a nucleic acid or vector of the present disclosure. In some embodiments, the cell can be a prokaryotic cell, a fungal cell, a yeast cell, or a higher eukaryotic cell such as a mammalian cell. Suitable prokaryotic cells include, but are not limited to, true bacteria, such as gram-negative or gram-positive organisms, such as Enterobacteriaceae, such as Escherichia, such as Escherichia coli; Enterobacter; Erwinia; Klebsiella; Proteus; Salmonella, such as Salmonella typhimurium; Serratia, such as Serratia marcescens. marcescans;And Shigella;Bacilli (Bacilli), such as Bacillus subtilis (B.subtilis) and Bacillus licheniformis (B.licheniformis); Pseudomonas (Pseudomonas), such as Pseudomonas aeruginosa (P.aeruginosa); And Streptomyces (Streptomyces). In some embodiments, the cell is a human cell. In some embodiments, the cell is an immune cell. In some embodiments, the host cell includes, for example, CHO cells, such as CHO-S cells and CHO-K1 cells, or HEK293 cells, such as HEK293A, HEK293T and HEK293FS.
[0109] In yet another aspect, the present disclosure provides a pharmaceutical composition comprising the antibody or antigen-binding fragment thereof of the present disclosure, and a pharmaceutically acceptable carrier or excipient.
[0110] The term "pharmaceutically acceptable" means that the carrier or adjuvant is compatible with the other ingredients of the composition and not substantially toxic to the recipient thereof, and / or that the carrier or adjuvant is approved or available for inclusion in pharmaceutical compositions for parenteral administration to humans.
[0111] In some embodiments, carriers or excipients used with the compositions of the present disclosure include, but are not limited to, maleic acid, tartaric acid, lactic acid, citric acid, acetic acid, sodium bicarbonate, sodium phosphate, histidine, glycine, sodium chloride, potassium chloride, calcium chloride, zinc chloride, water, dextrose, N-methylpyrrolidone, dimethyl sulfoxide, N,N-dimethylacetamide, ethanol, propylene glycol, polyethylene glycol, diethylene glycol monoethyl ether, and the surfactant polyoxyethylene-sorbitan monooleate.
[0112] In some embodiments of the pharmaceutical composition of the present disclosure, the pharmaceutical composition further comprises a second therapeutic agent. In some embodiments, the second therapeutic agent can be selected from antibodies, chemotherapeutic agents and small molecule drugs.
[0113] In some embodiments, the second therapeutic agent can be selected from antiviral agents (such as zidovudine, acyclovir, ganciclovir, vidarabine, herpes, trifluridine and ribavirin, foscarnet, amantadine, rimantadine, tiaquinol, indinavir, ritonavir, alpha interferon, etc.), antibacterial agents (such as penicillin, cephalosporin, imipenem, axtreonam, vancomycin, cycloserine, bacitracin, chloramphenicol, etc.), amphotericin B, nystatin, ketoconazole, isoniazid, metronidazole, pentamidine), antifungal agents (eg, azoles, imidazoles, triazoles, itraconazole, polyenes, amphotericin B, fluconazole, flucytosine, ketoconazole, caspofungin acetate, chloramphenicol ... acetate), voriconazole, etc.), anti-angiogenic agents, TNF-α antagonists, immunomodulators (such as methotrexate, leflunomide, cyclophosphamide, cyclophosphamide, Immuran, cyclosporine A, minocycline, azathioprine, etc.), anticancer agents (not limited to peptides, polypeptides, fusion proteins, nucleic acid molecules, small molecules, mimetics, synthetic drugs, inorganic molecules and organic molecules), mast cell modulators, and anti-inflammatory agents (such as adrenocortical hormones, corticosteroids (such as beflumethasone, budesonide, 9-deflurane, fluticasone, triamcinolone, methylprednisolone, prednisolone, prednisone, hydrocortisone), glucocorticoids, steroids, nonsteroidal anti-inflammatory drugs (such as aspirin, ibuprofen, diclofenac sodium, COX-2 inhibitors), and leukotriene antagonists (such as montelukast, methylflavonoids purine, zafirlukast and zylueton), β2 agonists (such as salbutamol, biterol, phenproterenol, isoetharie, isoproterenol, pirbuterol, salbutamol, terbutaline formoterol, salmeterol and salbutamol terbutaline)), Vitaxin, siplizumab, antihistamines (such as diphenhydramine, chlorpheniramine, desensitizer, bromopheniramine, chlorpheniramine, pyrrolidine, promethazine, hydroxyzine, astemizole, azatadine, cetirizine, cyproheptadine, loratadine, fexofenadine), anti-EphA2 antibodies, and common traditional Chinese medicine active ingredients and extracts (such as anti-inflammatory, anticancer active small molecules, polysaccharide extracts (such as ginseng polysaccharides, dendrobium polysaccharides, poria polysaccharides, ganoderma lucidum polysaccharides, cordyceps polysaccharides, wolfberry polysaccharides, tremella polysaccharides, etc.)) and any combination thereof.
[0114] In another aspect, the present disclosure provides a method for preventing or treating a disease in a subject, such as a disease associated with abnormal expression of IL-9, comprising administering to the subject a therapeutically effective amount of an antibody or antigen-binding fragment thereof of the present disclosure or a pharmaceutical composition of the present disclosure. In yet another aspect, the present disclosure provides a use of an antibody or antigen-binding fragment thereof of the present disclosure or a pharmaceutical composition of the present disclosure in the preparation of a medicament for preventing or treating a disease in a subject, such as a disease associated with abnormal expression of IL-9.
[0115] As used herein, "prevention" means that a therapeutically effective amount of an antibody or its antigen-binding fragment, or a pharmaceutical composition of the present disclosure is applied to a subject so as to protect the subject from the occurrence of a disease associated with abnormal expression of IL-9. When the term "prevention" used herein is related to a given treatment for a given condition (e.g., preventing a disease associated with abnormal expression of IL-9), it is intended that the subject of the treatment does not develop a clinically observable level of the condition at all, or develops more slowly and / or to a less severe degree than a subject without treatment. These terms are not limited to situations in which the subject does not experience any condition. For example, if treatment is given during exposure of the patient to a stimulus expected to produce a given condition manifestation, and the treatment causes the subject to experience less and / or milder symptoms of the condition than expected when not given, then it can be considered that the treatment has prevented the condition.
[0116] As used herein, "treatment" refers to a method for obtaining a beneficial or desired result (including clinical results). For the purposes of the present invention, beneficial or desired clinical results include, but are not limited to, one or more of the following: alleviating one or more symptoms caused by the disease, reducing the degree of the disease, stabilizing the disease (e.g., preventing or delaying the deterioration of the disease), preventing or delaying the spread of the disease, preventing or delaying the recurrence of the disease, delaying or slowing down the progress of the disease, improving the disease state, providing relief (partially or completely) of the disease, reducing the dosage of one or more other drugs required for treating the disease, delaying the progress of the disease, improving or improving the quality of life, weight gain and / or prolonging the survival period. The method of the present invention contemplates any one or more of these aspects of treatment.
[0117] In certain embodiments, treatment can be given after one or more symptoms have occurred. In other embodiments, treatment can be given in the absence of symptoms. For example, treatment can be given to susceptible individuals before the onset of symptoms, or another damaging agent can be used for treatment (for example, according to symptom history, according to heredity or other susceptibility factors, disease therapy or any combination thereof). Treatment can also be continued after symptoms have subsided, for example, to prevent or delay their recurrence.
[0118] As used herein, "administering" refers to introducing an antibody or composition into a subject, and includes introducing an antibody or composition in parallel or sequentially. "Administering" may refer to, for example, treatment, pharmacokinetics, diagnosis, research, placebo, and experimental methods. "Administering" also encompasses in vitro and ex vivo treatments. Compositions or agents are introduced into subjects by any suitable route, and examples of suitable methods for administering antibodies or compositions of the present disclosure include oral, intradermal, subcutaneous, intramuscular, intraosseous, intraperitoneal, and intravenous injections, as well as systemic administration or topical administration to the vicinity of the target site, but are not limited thereto. Administration includes self-administration and administration by others. Administration may be performed by any suitable route. Suitable routes of administration allow compositions or agents to perform their intended functions. For example, if the suitable route is intravenous, the compositions are administered by introducing the antibody or composition into the vein of the subject.
[0119] In certain embodiments of the present disclosure, the antibodies or compositions of the present disclosure are packaged with or stored in a device for administration. Devices for injectable formulations include, but are not limited to, injection ports, automatic syringes, injection pumps, and injection pens. Devices for aerosol or powder formulations include, but are not limited to, inhalers, insufflators, aspirators, and the like. Thus, the present disclosure includes an administration device comprising an antibody or composition of the present disclosure for treating or preventing one or more conditions described herein.
[0120] The "subjects" contemplated for administration include, but are not limited to, humans (i.e., males or females of any age group, such as pediatric subjects (e.g., infants, children, adolescents) or adult subjects (e.g., young adults, middle-aged adults, or elderly people)) and / or other non-human animals, such as mammals (e.g., primates).
[0121] In some embodiments of the methods or uses disclosed herein, the disease may be a respiratory disease, an autoimmune disease, or a blood cancer (e.g., a leukemia, a plasma cell malignancy, or a lymphoma). In some embodiments, the disease may be selected from acute infectious pneumonia, hypersensitivity pneumonitis, bronchial asthma, chronic obstructive pulmonary disease, pulmonary fibrosis (e.g., pulmonary fibrosis due to various causes, idiopathic pulmonary fibrosis), systemic lupus erythematosus, rheumatoid arthritis, systemic vasculitis, scleroderma, dermatomyositis, mixed connective tissue disease, allergic rhinitis, allergic conjunctivitis, autoimmune hemolytic anemia, thyroid autoimmune disease, ulcerative colitis, Sjögren's syndrome, psoriatic arthritis, multiple sclerosis, Chronic lymphocytic thyroiditis, insulin-dependent diabetes mellitus, myasthenia gravis, pernicious anemia with chronic atrophic gastritis, Goodpasture's syndrome, pemphigus vulgaris, pemphigoid, multiple sclerosis, acute idiopathic polyneuritis, autoimmune adrenal insufficiency, chronic myeloid leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, acute lymphocytic leukemia, multiple myeloma, monoclonal gammopathy of undetermined significance (MGUS), non-Hodgkin's lymphoma, and Hodgkin's lymphoma.
[0122] In some embodiments of the methods or uses of the present disclosure, preventing or treating a disease in a subject further comprises administering a second therapeutic agent to the subject.
[0123] In some embodiments, the second therapeutic agent can be selected from antiviral agents (such as zidovudine, acyclovir, ganciclovir, vidarabine, herpes, trifluridine and ribavirin, foscarnet, amantadine, rimantadine, tiaquinol, indinavir, ritonavir, alpha interferon, etc.), antibacterial agents (such as penicillin, cephalosporin, imipenem, axtreonam, vancomycin, cycloserine, bacitracin, chloramphenicol, etc.), amphotericin B, nystatin, ketoconazole, isoniazid, metronidazole, pentamidine), antifungal agents (eg, azoles, imidazoles, triazoles, itraconazole, polyenes, amphotericin B, fluconazole, flucytosine, ketoconazole, caspofungin acetate, chloramphenicol ... acetate), voriconazole, etc.), anti-angiogenic agents, TNF-α antagonists, immunomodulators (such as methotrexate, leflunomide, cyclophosphamide, cyclophosphamide, Immuran, cyclosporine A, minocycline, azathioprine, etc.), anticancer agents (not limited to peptides, polypeptides, fusion proteins, nucleic acid molecules, small molecules, mimetics, synthetic drugs, inorganic molecules and organic molecules), mast cell modulators, and anti-inflammatory agents (such as adrenocortical hormones, corticosteroids (such as beflumethasone, budesonide, 9-deflurane, fluticasone, triamcinolone, methylprednisolone, prednisolone, prednisone, hydrocortisone), glucocorticoids, steroids, nonsteroidal anti-inflammatory drugs (such as aspirin, ibuprofen, diclofenac sodium, COX-2 inhibitors), and leukotriene antagonists (such as montelukast, methylflavonoids purine, zafirlukast and zylueton), β2 agonists (such as salbutamol, biterol, phenproterenol, isoetharie, isoproterenol, pirbuterol, salbutamol, terbutaline formoterol, salmeterol and salbutamol terbutaline)), Vitaxin, siplizumab, antihistamines (such as diphenhydramine, chlorpheniramine, desensitizer, bromopheniramine, chlorpheniramine, pyrrolidine, promethazine, hydroxyzine, astemizole, azatadine, cetirizine, cyproheptadine, loratadine, fexofenadine), anti-EphA2 antibodies, and common traditional Chinese medicine active ingredients and extracts (such as anti-inflammatory, anticancer active small molecules, polysaccharide extracts (such as ginseng polysaccharides, dendrobium polysaccharides, poria polysaccharides, ganoderma lucidum polysaccharides, cordyceps polysaccharides, wolfberry polysaccharides, tremella polysaccharides, etc.)) and any combination thereof. Example
[0124] The present invention is further illustrated by the following examples, but any example or combination thereof should not be construed as limiting the scope or implementation of the present invention. The scope of the present invention is defined by the appended claims. In combination with this specification and common knowledge in the art, a person of ordinary skill in the art can clearly understand the scope defined by the claims. Without departing from the spirit and scope of the present invention, a person of ordinary skill in the art can make any modification or change to the technical solution of the present invention, and such modification and change are also included in the scope of the present invention.
[0125] Example 1: Preparation and detection of purified antibodies
[0126] 1. Preparation of Fc-IL-9 and IL-9-His recombinant proteins
[0127] The coding sequence of the synthesized IL-9 fragment (Glu19-Ile144) was added with Fc and His tags at the N-terminus and / or C-terminus, respectively, and subcloned into the eukaryotic expression vectors pcDNA3.4-His and pLVX-puro to construct antigen expression vectors. The obtained vectors were named pcDNA3.4-IL9(19-144)-His(P15248) and pLVX-Fc2-IL9(19-144)-Puro, respectively. The recombinant protein for immunization and antibody screening was obtained by transient transfection of 293F cells.
[0128] The purified Fc-IL-9 and IL-9-His recombinant proteins were subjected to SDS-PAGE detection. SDS-PAGE detection results ( Figure 1 ) showed that the size of Fc-IL-9 recombinant protein was about 40kD, the size of IL-9-His recombinant protein was about 30kD, and the purity of Fc-IL-9 and IL-9-His recombinant proteins was greater than 80%, which could be used for immune and titer detection.
[0129] 2. Preparation of CHO-S-IL-9 membrane-expressing cell line
[0130] The codon-optimized IL-9 sequence gene was synthesized and subcloned into the lentiviral expression vector Lenti-CMV-puro to prepare a target gene overexpression lentiviral vector. The constructed overexpression lentiviral vector was used to prepare lentivirus, infect CHO-S cells and screen stable cell lines. The CHO-S cell line was incubated with the IL-9 positive control antibody 7F3com (see patent CN1809383A), and the expression of the target gene was detected by flow cytometry fluorescence sorting (FACS). The 7F3com antibody has the following VH and VL sequences:
[0131] 7F3com-VH (SEQ ID NO: 34)
[0132] QVQLVQSGAEVKKPGSSVKVSCKASGGTFSYYWIEWVRQAPGQ
[0133] GLEWMGEILPGSGTTNPNEKFKGRVTITADESTSTAYMELSSLRSE
[0134] DTAVYYCARADYYGSDYVKFDYWGQGTLVTVSS
[0135] 7F3com-VL (SEQ ID NO: 35)
[0136] DIQMTQSPSSSLSASVGDRVTITCKASQHVITHVTWYQQKPGKAPK
[0137] LLIYGTSYSYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQFY
[0138] EYPLTFGGGTKVEIK
[0139] like Figure 2 As shown, the results indicate that a CHO-S-IL-9 membrane-expressing cell line that can be used for immune titer detection and antibody binding has been successfully screened.
[0140] 3. Mouse Immunization and Detection
[0141] Ten female mice aged 6-8 weeks (SPF grade, 5 each of Balb / C and CD-1 strains, labeled 61-70) were immunized by subcutaneous injection at multiple points using 100 μg / mouse of Fc-IL-9 recombinant protein expressed at 1 mg / ml. Three immunizations were performed by subcutaneous injection on days 0, 15, and 30, respectively. After immunization, 10 μL of blood was collected from the eye sockets of the mice, and serum was obtained by centrifugation. The serum was graded diluted and then tested by enzyme-linked immunosorbent assay (ELISA). At the same time, the serum was diluted 1:1000 for FACS detection. Based on the results of ELISA and FACS detection, mice No. 66 and No. 70 with better immune titer detection were selected for impact immunization and hybridoma fusion by intraperitoneal injection.
[0142] 4. Hybridoma fusion and screening
[0143] After 3 days of shock immunization, the mice were killed and the spleen of the mice was obtained under sterile conditions to prepare a single cell suspension of B cells. The single cell suspension of B cells was mixed with non-secretory SP2 / 0 myeloma cells (Shanghai Cell Bank, Chinese Academy of Sciences, catalog number: TCM42) and cell fusion was performed using a BTX cell electrofusion instrument. The fused cells were cultured in complete medium for about 10 days, and then the medium was replaced with HT medium. After 2 days of continuous culture, the supernatant was taken for detection of specific antibodies.
[0144] Specifically, the culture supernatant was tested for binding to IL-9-His by ELISA, and the titer of the fusion clones was detected by FACS using CHO-S-IL-9 membrane-expressing cells and CHO-S cells, and clones with strong binding were screened for subcloning. After the subcloning was completed, it was identified by ELISA and FACS, and repeated for multiple rounds until a monoclone was formed. The negative control (NC) used in the test was PBS, and the positive control (PC) was an immune serum diluted 1:1000. Finally, clones with high fluorescence values and good growth were selected to express purified antibodies based on the test results.
[0145] 5. Purified Antibody Testing
[0146] 5.1 ELISA and EC of purified antibodies 50 statistics
[0147] ELISA was performed according to standard protocols to determine the affinity of the purified antibody to the IL-9-His recombinant protein. In brief, the IL-9-His recombinant protein was diluted with sterile PBS and added to a 96-well plate at 100 μL / well for overnight coating at 4°C, and then blocked with blocking buffer. Add 100 μl of gradient diluted purified IL-9 antibody and incubate at room temperature for 1 hour. The control wells were PBS. Wash the plate three times with PBST and add 100 μL of HRP anti-mouse IgG H&L (Biolon, CAT#BF03001) and incubate at room temperature for 1 hour. Wash the plate three times with PBST and develop with TMB colorimetric solution at room temperature. Use a microplate reader to read the OD value in the well. PRISM GraphPad was used to process the data, draw curves, and calculate the EC of each candidate antibody. 50 Table 1 shows the EC values of the affinity of 44 purified antibodies to IL-9-His recombinant protein. 50 Statistical results.
[0148]
[0149] 5.2 Detection of blocking activity of purified antibodies
[0150] The coding sequence of IL-9 receptor (IL-9R) was constructed into the eukaryotic expression vector pLVX-Hygro. The constructed vector was used to infect 293F cells and the 293-IL-9R cell line was screened for antibody blocking activity detection. The IL-9 recombinant protein was incubated with IL-9R, and the flow cytometry test results showed that the IL-9 recombinant protein could specifically bind to IL-9R.
[0151] According to standard protocols, the blocking activity of purified antibodies was detected by flow cytometry to detect the effect of biotin-conjugated IL-9-Fc (Biotin-IL-9-Fc) on the binding ability of 293-IL-9R recombinant cell lines. Briefly, 293-IL-9R cells in logarithmic growth phase were resuspended in PBS and the cell density was adjusted to 3×10 6 / mL, add 100μL / well to a 96-well U-shaped plate, add 20μg / mL of the purified IL-9 antibody to be tested and 20μg / mL of Biotin-IL-9-Fc, and incubate at 4°C for 1h. After washing once with PBS, add the secondary antibody (APC-Streptavidin, Biolegend, CAT#405207) at 100μL / well and incubate at 4°C for 45min. After washing with PBS, resuspend in PBS for flow cytometry detection. PC is the IL-9 positive antibody 7F3com.
[0152] According to the results of ELISA and flow cytometry in blocking experiment ( Figure 3 ), five purified antibodies, 38-D8-C7-G9, 31-D6-B8-B8, 29-B9-F5-B6, 22-F2-E9-C8 and 43-C3-A10-F12 (renumbered A1-A5, respectively), were selected for further hybridoma sequencing.
[0153] 6. Hybridoma Sequencing
[0154] Total RNA of hybridoma cells was extracted according to standard protocols and reverse transcribed into cDNA samples. The heavy and light chain variable regions of the antibody were amplified by PCR using hybridoma sequencing primers, followed by TA cloning, and the fragments obtained by PCR were subcloned into T vectors, and clones were selected for sequencing. The hybridoma sequencing results are shown in Table 2 below, where A4 and A5 sequences are identical.
[0155] Table 2. CDR sequences, VH sequences and VL sequences of A1-A5 antibodies
[0156]
[0157]
[0158]
[0159] Example 2: Preparation and detection of chimeric antibodies
[0160] 1. Construction and verification of chimeric antibody expression vector
[0161] The antibody heavy chain variable region obtained by hybridoma sequencing was subcloned into the pcDNA3.4-IgG1 expression vector, and the light chain variable region was subcloned into the pcDNA3.4-IgKc expression vector ( Figure 4 ). The constructed heavy chain and light chain expression vectors were transiently co-transfected into 293F cells (serum-free culture), and the supernatant was collected for ELISA detection. The ELISA method is as described in 5.1 of Example 1. The detection results are shown in Table 3 below.
[0162] Table 3. Expression detection results of chimeric antibodies
[0163]
[0164] The results showed that the four chimeric antibodies (CA1-CA4) could specifically bind to IL-9. The chimeric antibodies were further expressed, purified and tested for their blocking activity.
[0165] 2. Expression, purification and blocking activity detection of chimeric antibodies
[0166] Add 2mL / well PBS to a 6-well plate, then add pcDNA3.4-IgG1 and pcDNA3.4-IgKc expression vectors respectively, pipette up and down to mix thoroughly, add LVTransm transfection reagent, and let stand at room temperature for 10 minutes. Add DNA / LVTransm complex to 293F cells and mix thoroughly. Place cells in a 37°C, 5% CO2 incubator and continue to culture. Collect the culture supernatant by centrifugation, filter, transfer the filtrate to a sterile centrifuge tube, and purify the chimeric antibody using a Protein A affinity column.
[0167] The chimeric antibody was diluted in a gradient manner, and its effect on the binding ability of Biotin-IL-9-Fc and 293-IL-9R recombinant cell line was detected by flow cytometry to detect its blocking activity. PC is IL-9 positive antibody 7F3com. According to the detection results of flow cytometry ( Figure 5 ), CA1-CA4 four chimeric antibodies all have high blocking activity. In the following examples, 38-D8-C7-G9 chimeric antibody (CA1 antibody) was used as an example for antibody humanization design.
[0168] Example 3: Construction and detection of humanized antibodies
[0169] 1. Humanized antibody design
[0170] Humanization design was performed based on the amino acid sequence information of the heavy and light chain variable regions of the mouse antibody, keeping the CDR region sequence of the original antibody unchanged. Different human antibody templates were selected for the heavy and light chains according to the results of germline alignment and antibody structure simulation, and back mutations were performed in the framework region after humanization to design candidate humanized antibody sequences (Table 4).
[0171] Table 4. Humanized antibody sequences
[0172]
[0173]
[0174] 2. Humanized antibody gene synthesis and expression vector construction
[0175] The heavy chain and light chain of the humanized antibody designed above were synthesized separately, and the heavy chain was subcloned into the pcDNA3.4-IgG1 expression vector, and the light chain was subcloned into the pcDNA3.4-IgKc expression vector (the vector schematic diagram is shown in Figure 4 After the vector was verified to be correct by sequencing, the endotoxin-free plasmid was prepared.
[0176] 3. Expression and detection of humanized antibodies
[0177] The humanized antibody expression vectors containing the designed heavy chain or light chain sequences were combined in pairs, transiently transfected into 293F cells, and then the culture supernatant was collected. According to the standard protocol (reference Example 1, Section 5.1), the human-mouse chimeric antibody CA1 constructed with the original mouse antibody VH and VL was used as a control, and the binding of the humanized antibody to the target antigen was detected by ELISA. The ELISA method is as described in 5.1 in Example 1. The results showed that the detected VH1+VL1, VH1+VL2, VH1+VL3, VH1+VL4, VH2+VL1, VH2+VL3, VH2+VL4, VH3+VL1, VH3+VL3, VH3+VL4, VH4+VL1, and VH4+VL3 combinations were all able to bind to IL-9 with high affinity, and their binding was basically consistent with that of the chimeric antibody. In subsequent experiments, four combinations of VH1-VL2, VH1-VL4, VH2-VL4 and VH3-VL4 (hu.CA1-hu.CA4) were used as examples to purify antibodies and perform functional tests.
[0178] 4. Purification and functional testing of humanized antibodies
[0179] The pcDNA3.4-IgG1 and pcDNA3.4-IgKc expression vectors corresponding to the selected antibody heavy chain / light chain combination were transfected into 293F cells using LVTransm transfection reagent. After culturing the cells, centrifugation was performed to collect the culture supernatant, and the antibodies were purified using a Protein A affinity column. According to standard protocols, the affinity and blocking activity of the purified humanized antibodies were detected by ELISA (controls were 38-D8-C7-G9 (CA1) chimeric antibodies and IL-9 positive antibodies 7F3com) and flow cytometry (controls were 38-D8-C7-G9 (CA1)).
[0180] The results show that Fig. 6A and 6B ), the affinity of humanized antibody, chimeric antibody and positive control antibody was consistent. In subsequent experiments, the affinity was tested by taking VH1-VL4 (hu.CA2) and VH1-VL2 (hu.CA1) as examples.
[0181] 5. Humanized Antibody Affinity Testing
[0182] The affinity of humanized antibodies was detected by ForteBio (BLI). Protein A sensor (Sartorius, Cat#18-5010) was used to immobilize chimeric (as a control) and humanized antibodies, respectively, with an immobilization height of about 1 nm. The buffer was PBS, and the antigen protein samples were gradiently diluted to 125, 62.5, 31.25, 15.625, 7.81 and 0 nM. The affinity detection procedure was equilibrium 60 s, binding 180 s, and dissociation 180 s.
[0183] The results of affinity test of purified humanized antibody are as follows Figures 7A-7C and as shown in the following Table 5. The results showed that the signal was concentration-dependent.
[0184] Table 5. Affinity test results
[0185]
[0186] Example 4: IL-9 antibody treatment of mouse pulmonary fibrosis disease model
[0187] Materials and methods
[0188] 6-8 week old male C57BL / 6J mice (purchased from Guangdong Sijia Jingda Biotechnology Co., Ltd., license number: SCXK (Guangdong) 2020-0052) were grouped, modeled and administered according to the schemes shown in Tables 6 and 7 below. Bleomycin (Nippon Kayaku Co., Ltd., 15 mg powder, dosage 1.5 mg / kg) and silicon dioxide (SiO2, Sigma, S5631-500g, dosage 2.5 mg / mouse) were used for modeling on day 0 (D0), and administration began on day 1 (D1), using normal saline as the antibody solvent. The positive drug pirfenidone (Beijing Contini Pharmaceutical Co., Ltd., 100 mg capsule) was used in the positive control group, and the humanized antibody hu.CA1 (VH1-VL2) of the present application was used in the IL-9 antibody group.
[0189] Table 6. Bleomycin model group
[0190]
[0191] Table 7. Silica model group
[0192]
[0193]
[0194] a: One animal died on D8 due to an error in the intragastric administration. The number of animals in this group was 10 at the end of the experiment.
[0195] The mice were weighed every day. After 21 days of administration in the bleomycin model group and 30 days of administration in the silica model group, the mice were killed to obtain lung tissue. The lung tissue was stained to detect the pathological changes of the lung tissue. Specifically, HE staining (HE staining kit purchased from Shanghai Biyuntian Biological Company, C0105M) was used to detect the degree of alveolar inflammation, and Masson staining (Masson staining kit purchased from Nanjing Jiancheng Biological Company, D026-1-2) was used to detect the degree of pulmonary fibrosis. The scoring criteria for HE staining and Masson staining are shown in Tables 8 and 9, respectively (refer to references: Matute-Bello G, Downey G, Moore BB, et al. An official American Thoracic Society workshop report: features and measurements of experimental acute lung injury in animals. Am J Respir Cell Mol Biol. 2011; 44(5): 725-738. doi: 10.1165 / rcmb.2009-0210ST and Lee Hyun Ju, Goo Jin Mo, Kim Na Ra et al. Semiquantitative measurement of murine bleomycin-induced lung fibrosis in in vivo and postmortem conditions using microcomputed tomography: correlation with pathologic scores--initial results. [J]. Invest Radiol, 2008, 43: 453-60).
[0196] Table 8. HE staining inflammatory scoring criteria
[0197]
[0198] Score=[(20*A)+(14*B)+(7*c)+(7*D)+(2*E)] / (f,@iaa*100)
[0199] Table 9. Masson staining fibrosis scoring criteria
[0200]
[0201] result
[0202] The body weight of bleomycin mouse model group Fig. 8A The results showed that except for the blank control group, the weight of mice decreased after modeling until the weight increased on the 10th day (D10) of administration. The weight change trend of the negative control group, positive control group and IL-9 antibody group was consistent during the administration. The weight of the silica mouse model group is shown in Figure 8B As shown. The results showed that except for the blank control group, the weight of the mice decreased after modeling, until the weight rebounded on the third day (D3) of administration, and the weight returned to the weight before modeling on the 12th day (D12) of administration. The weight change trend of the negative control group, positive control group and IL-9 antibody group during the administration process was consistent. The above results show that IL-9 antibody has good safety.
[0203] The results of HE staining and inflammatory score of the bleomycin mouse model group were as follows: Fig. 9A and 9B As shown. The results showed that the lung tissue structure of mice in the negative control group was severely damaged, with more bleeding spots and inflammatory cell infiltration. The lung tissue structure of the positive control group and the IL-9 antibody group improved after drug treatment, and the bleeding spots decreased. The inflammatory score results showed that both IL-9 antibody and pirfenidone could significantly reduce the inflammatory score, and the inflammatory score of the IL-9 antibody group was slightly lower, indicating that IL-9 antibody has a significant therapeutic effect on pulmonary fibrosis.
[0204] The results of Masson staining and fibrosis score in the bleomycin mouse model group were as follows: Fig. 10A and 10B As shown. The results showed that compared with the blank control group, the blue collagen fibers in the lung tissue of mice in the negative control group increased significantly. The collagen fibers and fibrosis areas in the lung tissue of the positive control group and the IL-9 antibody group were significantly reduced after drug treatment. The fibrosis score results showed that both IL-9 antibody and the positive drug pirfenidone significantly reduced the fibrosis score, indicating that IL-9 antibody has a significant therapeutic effect on pulmonary fibrosis.
[0205] The results of HE staining and inflammatory score of silica mouse model group were as follows Fig.11A and 11B As shown. The results showed that the negative control group mice had more inflammatory cell infiltration in the lung tissue, severe damage to the lung tissue structure, and more bleeding points. The lung tissue structure of the positive control group and the IL-9 antibody group improved after drug treatment, and the infiltration area decreased. The inflammatory score results showed that both IL-9 antibody and the positive drug pirfenidone could significantly reduce the inflammatory score, indicating that IL-9 antibody has a significant therapeutic effect on pulmonary fibrosis.
[0206] The results of Masson staining and fibrosis score in the silica mouse model group were as follows Fig. 12A and12B As shown. The results showed that compared with the blank control group, the blue collagen fibers in the lung tissue of mice in the negative control group increased significantly, and there were more bleeding spots in the lung tissue. After treatment, the collagen fibers and fibrosis areas in the lung tissue of the positive control group and the IL-9 antibody group were significantly reduced. The fibrosis score results showed that both IL-9 antibody and the positive drug pirfenidone could reduce the fibrosis score, indicating that IL-9 antibody has a significant therapeutic effect on pulmonary fibrosis.
Claims
1. An antibody or antigen-binding fragment thereof that specifically binds to interleukin-9 (IL-9), comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein (i) the VH comprises CDR-H1, CDR-H2 and CDR-H3 having the amino acid sequences shown in SEQ ID NOs: 22-24, respectively, and the VL comprises CDR-L1, CDR-L2 and CDR-L3 having the amino acid sequences shown in SEQ ID NO: 12, amino acid AAT and SEQ ID NO: 13, respectively; or (ii) the VH comprises CDR-H1, CDR-H2 and CDR-H3 having the amino acid sequences shown in SEQ ID NOs: 8-10, respectively, and the VL comprises CDR-L1, CDR-L2 and CDR-L3 having the amino acid sequences shown in SEQ ID NO: 12, amino acid AAT and SEQ ID NO: 13, respectively; or (iii) the VH comprises CDR-H1, CDR-H2 and CDR-H3 having the amino acid sequences shown in SEQ ID NOs: 15-17, respectively, and the VL comprises CDR-L1, CDR-L2 and CDR-L3 having the amino acid sequences shown in SEQ ID NO: 19, amino acid YAS and SEQ ID NO: 20, respectively.
2. The antibody or antigen-binding fragment thereof of claim 1, wherein (i) the VH comprises an amino acid sequence having at least 90%, at least 95%, at least 98%, at least 99% or 100% sequence identity to SEQ ID NO: 25, and the VL comprises an amino acid sequence having at least 90%, at least 95%, at least 98%, at least 99% or 100% sequence identity to SEQ ID NO: 14; or (ii) the VH comprises an amino acid sequence having at least 90%, at least 95%, at least 98%, at least 99% or 100% sequence identity to SEQ ID NO: 11, and the VL comprises an amino acid sequence having at least 90%, at least 95%, at least 98%, at least 99% or 100% sequence identity to SEQ ID NO: 14; or (iii) the VH comprises an amino acid sequence having at least 90%, at least 95%, at least 98%, at least 99% or 100% sequence identity to SEQ ID NO:18, and the VL comprises an amino acid sequence having at least 90%, at least 95%, at least 98%, at least 99% or 100% sequence identity to SEQ ID NO:
21.
3. The antibody or antigen-binding fragment thereof of claim 2, wherein (i) the VH comprises the amino acid sequence shown in SEQ ID NO: 25, and the VL comprises the amino acid sequence shown in SEQ ID NO: 14; or (ii) the VH comprises the amino acid sequence shown in SEQ ID NO: 11, and the VL comprises the amino acid sequence shown in SEQ ID NO: 14; or (iii) the VH comprises the amino acid sequence shown in SEQ ID NO: 18, and the VL comprises the amino acid sequence shown in SEQ ID NO:
21.
4. The antibody or antigen-binding fragment thereof according to any one of claims 1 to 3, wherein the antibody is selected from the group consisting of IgG, IgA, IgM, IgE and IgD isotypes.
5. The antibody or antigen-binding fragment of claim 4, wherein the antibody is selected from the group consisting of IgG1, IgG2, IgG3 and IgG4 subtypes.
6. The antibody or antigen-binding fragment thereof according to any one of claims 1 to 5, wherein the antibody is selected from the group consisting of a murine antibody, a chimeric antibody, a humanized antibody and a fully human antibody.
7. The antibody or antigen-binding fragment thereof according to any one of claims 1 to 6, wherein the antigen-binding fragment is selected from the group consisting of Fab, Fab', F(ab')2, Fv, scFv and ds-scFv.
8. The antibody or antigen-binding fragment thereof according to any one of claims 1 to 7, wherein the antibody is a bispecific antibody or a multispecific antibody.
9. A nucleic acid comprising a nucleotide sequence encoding the antibody or antigen-binding fragment thereof according to any one of claims 1 to 8.
10. A vector comprising a nucleotide sequence encoding the antibody or antigen-binding fragment thereof according to any one of claims 1 to 8.
11. A host cell comprising the nucleic acid of claim 8 or the vector of claim 10.
12. A pharmaceutical composition comprising the antibody or antigen-binding fragment thereof according to any one of claims 1 to 8, and a pharmaceutically acceptable carrier or excipient.
13. The pharmaceutical composition of claim 12, further comprising a second therapeutic agent.
14. The pharmaceutical composition of claim 13, wherein the second therapeutic agent is selected from the group consisting of an antibody, a chemotherapeutic agent, and a small molecule drug.
15. The pharmaceutical composition of claim 13 or 14, wherein the second therapeutic agent is selected from antiviral agents, antibacterial agents, antifungal agents, TNF-α antagonists, immunomodulators, anticancer agents, and common traditional Chinese medicine active ingredients and extracts, and combinations thereof.
16. The pharmaceutical composition of claim 15, wherein the immunomodulator is selected from the group consisting of mast cell modulators, anti-inflammatory agents, and antihistamines.
17. The pharmaceutical composition of claim 14 or 15, wherein the second therapeutic agent is selected from anti-angiogenic agents.
18. Use of the antibody or antigen-binding fragment thereof according to any one of claims 1 to 8 or the pharmaceutical composition according to any one of claims 12 to 17 for the preparation of a drug for treating a disease associated with abnormal expression of IL-9, The disease is selected from bronchial asthma, pulmonary fibrosis, lymphoma, systemic lupus erythematosus, rheumatoid arthritis, psoriatic arthritis and multiple sclerosis.
